Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Scientists discover unique insulin responses in each person, opening new paths for early diabetes detection and treatment.

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians recommending that many patients with diabetes take ...

Scientists have unearthed surprising details about how our bodies handle insulin – the hormone that plays a crucial role in ...

Scientists have unearthed surprising details about how our bodies handle insulin—the hormone that plays a crucial role in ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO ... In 2004, Levemir – a long-acting modern insulin – was launched. Under Sorensen, the company develops its first GLP-1 drug ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD ... Tresiba’s strong profile in the long-acting insulin market hasn’t been enough to defend it from US pricing pressure ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk .

Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...